Skip to content
Peptide research

Vesilute

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A dipeptide bioregulator (Glu-Asp) marketed for bladder and prostate health, meant to normalize detrusor muscle function and reduce urinary tract inflammation. The case is almost entirely speculative: claims for overactive bladder and prostate symptoms rest on limited mechanistic work, with no independent human validation. There is essentially no human safety data, and supply is unregulated research-grade. Not FDA-approved; contraindicated in pregnancy.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Vesilute is a synthetic 2-amino-acid peptide (Glu-Asp) from the Khavinson bioregulator family, designed to support bladder and urinary tract function. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it is the minimal synthesized version of Chitomur, a natural peptide complex extracted from animal bladder tissue. Vesilute is targeted at age-related urinary issues including overactive bladder, incontinence, and chronic bladder inflammation.

How it works in the body

A dipeptide bioregulator (Glu-Asp) that targets urinary tract and prostate tissue. It modulates gene expression in bladder smooth muscle cells and prostate epithelial cells, normalizing contractile function, inflammatory signaling, and cellular proliferation in the lower urinary tract.

Research overview

Vesilute is proposed to work through the Khavinson epigenetic mechanism — entering cells and interacting with DNA to normalize gene expression in bladder and urinary tract tissues, helping restore normal muscle contractility and reduce inflammation. The related polypeptide extract Vezusten showed improvements in urinary frequency and bladder capacity in a 2024 study of 20 women with overactive bladder. Earlier preclinical work demonstrated normalization of bladder muscle function in animal models of obstruction. However, the evidence base is extremely limited. The cited clinical studies concern other preparations; Vezusten has randomized trial evidence, but clinical benefit from isolated Vesilute remains unestablished. All research comes from Russian institutions affiliated with Khavinson's group, and no independent Western replication exists.

Who researches Vesilute?

Commonly researched by

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Extremely limited clinical evidence and lack of independent validation

    High

    PubMed and ClinicalTrials.gov searches for Vesilute return no primary clinical studies

  • Unproven efficacy of the isolated dipeptide vs. polypeptide extract

    High

    PMID 8330080 (prostatilen polypeptide extract, not the dipeptide)

  • Unregulated product quality (research-grade sources)

    High

    No Vesilute-specific FDA quality assessment identified. Vesilute is not named in FDA's May 14, 2026 503A categories document; that document does not establish this product's purity or sterility.

  • Contraindicated in pregnancy and lactation

    Moderate

    No published reproductive toxicity data; vendor labelling and standard precaution for unstudied bioregulators

  • Possible mild side effects (theoretical and vendor-reported)

    Low

    Vendor materials only; no indexed pharmacovigilance or trial safety data

Interaction summary(8)

Rated by direction with this peptide

  • Antimuscarinics for overactive bladder (oxybutynin, solifenacin, tolterodine, darifenacin)

    NeutralTheoretical

    No pharmacological conflict is expected, and both are proposed to reduce detrusor overactivity by different routes, but 'synergy' would be an efficacy claim the peptide's Speculative evidence base cannot support — additive benefit has never been tested. The practical caution is that any perceived benefit from the peptide could simply mask inadequate antimuscarinic titration.

    Mechanism-based inference; no published interaction or combination study (PMID 8330080 is the closest smooth-muscle datapoint)

  • Beta-3 adrenergic agonists (mirabegron, vibegron)

    NeutralTheoretical

    Combination with a detrusor-relaxing beta-3 agonist is mechanistically non-overlapping and would not be expected to conflict; no PK/PD data exist for a peptide added to this class, and no additive benefit has been demonstrated.

    Mechanism-based inference; no interaction study exists

  • Alpha-1 blockers for BPH/LUTS (tamsulosin, alfuzosin, doxazosin, silodosin)

    NeutralTheoretical

    Russian practice has used prostate peptide preparations as an adjunct alongside alpha-blockers for LUTS and no pharmacological conflict is expected, but the supporting data are for polypeptide extracts rather than the Glu-Asp dipeptide, are not independently validated, and note that prostatilen enhanced (not relaxed) bladder smooth-muscle contractility in the one indexed study, so even the mechanistic direction is unsettled.

    PMID 8330080 (prostatilen extract, prostate/bladder smooth muscle); no controlled combination trial

  • 5-alpha reductase inhibitors (finasteride, dutasteride)

    NeutralTheoretical

    No shared metabolic pathway or receptor target, so no interaction is anticipated; the practical concern is that adding an unvalidated peptide confounds the 6-12 month response assessment these drugs require.

    Mechanism-based inference; no published data

  • Androgen deprivation therapy or active prostate cancer surveillance

    CautionTheoretical

    A compound whose stated mechanism includes modulating prostate epithelial proliferation and gene expression should not be assumed safe in the presence of prostate malignancy or on ADT, and no oncology safety data exist; note that within this peptide family effects on carcinogenesis were inconsistent even in rodents.

    PMID 11785104 and PMID 11586406 (divergent effects of related peptides on induced rat bladder tumours); no human oncology safety data

  • Loop and thiazide diuretics

    CautionLow

    Diuretic-driven polyuria and urgency will dominate any lower-urinary-tract symptom picture, so combining them makes it effectively impossible to attribute symptom change to the peptide and risks over-treating a pharmacologic cause of frequency.

    Clinical pharmacology of diuretics; no direct interaction data

  • Antibiotics for urinary tract infection

    NeutralTheoretical

    No pharmacokinetic interaction is expected with a small dipeptide, but urinary symptoms attributed to the peptide's failure or success may in fact reflect an untreated or resolving infection, so infection should be excluded before drawing conclusions.

    Mechanism-based inference; no published interaction data

  • Other Khavinson-family bioregulator peptides (Vesugen, Epitalon, Vilon, Prostamax)

    NeutralTheoretical

    Using Vesilute with other ultrashort bioregulators has not been studied. No adverse combination has been documented, but overlapping unvalidated mechanisms would make attribution of both benefit and harm impossible.

    PMID 34834147 (class-level review); no combination studies published

Known risks(5)

  • Extremely limited clinical evidence and lack of independent validation

    Moderate-High

    Vezusten has multiple human studies, including a placebo-controlled randomized trial. These studies do not establish efficacy or safety of isolated Vesilute. No independent safety monitoring, pharmacovigilance, or large-scale safety trials exist. No FDA or EMA review of safety or efficacy has occurred. The absence of adverse events in published studies likely reflects very small sample sizes.

  • Unproven efficacy of the isolated dipeptide vs. polypeptide extract

    Moderate

    Clinical evidence comes from Vezusten (complex bovine bladder polypeptide extract), not from the isolated Vesilute Glu-Asp dipeptide. It is unknown whether the minimal dipeptide carries equivalent bioactivity to the full polypeptide complex. The assumption that a single dipeptide replicates the effects of a multi-peptide tissue extract has not been directly validated in clinical studies.

  • Unregulated product quality (research-grade sources)

    Moderate

    Unregulated Vesilute products sold online are not manufactured under pharmaceutical GMP standards and is not subject to FDA quality oversight. Purity, identity, and sterility may vary among unregulated products sold online. Research-grade products are unsuitable for human consumption. Contamination or incorrect peptide sequences are potential concerns.

  • Contraindicated in pregnancy and lactation

    Moderate (specific populations)

    Pregnancy and breastfeeding are listed as contraindications by manufacturers. Reproductive and developmental safety of isolated Vesilute remains unestablished. Vezusten's product information reports preclinical embryotoxicity and teratogenicity testing, which does not establish Vesilute's safety. As a gene-regulatory peptide, theoretical concerns about effects on developing tissues exist.

  • Possible mild side effects (theoretical and vendor-reported)

    Low

    Khavinson peptide bioregulators as a class are reported to have minimal side effects. Possible effects include individual intolerance/allergic reaction to peptide components or capsule excipients, mild gastrointestinal discomfort (nausea, bloating), and injection site reactions (if administered parenterally). No systematic safety reporting exists in Western medical literature.

Drug interactions(5)

  • Anticholinergic / antimuscarinic medications (oxybutynin, tolterodine, solifenacin)

    Vesilute targets bladder smooth muscle and detrusor function through peptide bioregulation. Anticholinergics are the standard first-line pharmacotherapy for overactive bladder and also act on detrusor smooth muscle. Concurrent use could theoretically result in additive or unpredictable effects on bladder contractility and urinary retention risk. No interaction studies have been conducted.

  • Beta-3 adrenergic agonists (mirabegron, vibegron)

    Beta-3 agonists relax the detrusor muscle to treat OAB. The ICS-EUS 2025 abstract (Abstract #99) references a randomized trial comparing bioregulatory peptides with beta-3 agonists for OAB treatment. Concurrent use may have additive effects on bladder relaxation. No formal interaction data exists.

  • Alpha-adrenergic blockers (tamsulosin, alfuzosin, doxazosin)

    Alpha-blockers are commonly used for BPH and lower urinary tract symptoms. Kuzmenko et al. 2021 demonstrated that bioregulatory peptides combined with alpha-blockers showed enhanced therapeutic benefit in BPH/prostatitis patients compared to alpha-blockers alone, suggesting these classes may be complementary. No adverse interactions were reported in that study.

  • Immunosuppressant medications

    Khavinson peptide bioregulators are proposed to regulate immune function at the tissue level. While Vesilute is not an immune-targeted peptide, its gene regulatory mechanisms could theoretically interact with immunosuppressive therapy. No interaction data exists. Manufacturers advise that individuals with severely weakened immune systems should proceed with medical guidance.

  • Other Khavinson peptide bioregulators (Prostamax, Chitomur, Pinealon)

    No adverse interactions between Khavinson bioregulators have been reported, though no formal interaction studies have been conducted.

Research & benefits

Evidence base

Evidence Level
Very Limited Evidence
Total Studies
5
Human Studies
1

The clinical evidence for Vesilute is extremely limited and relies substantially on studies of the related polypeptide extract Vezusten rather than the isolated Glu-Asp dipeptide. Human evidence cited here concerns Vezusten, not isolated Vesilute, and includes a 2022 placebo-controlled randomized trial as well as the 2024 cohort of 20 women with overactive bladder treated with intramuscular Vezusten injections, showing statistically significant improvements in urination frequency (14 to 11 per day, p<0.001), urge incontinence episodes (p=0.004), and maximum cystometric capacity (267 to 320 ml). Preclinical evidence demonstrates normalization of detrusor contractility in rat models with infravesical obstruction. The mechanistic rationale draws on the broader Khavinson short peptide framework, where dipeptides are shown to regulate gene expression through DNA interaction. Major limitations: the 2024 cohort was not randomized and was very small (n=20), the human studies used Vezusten (polypeptide extract) rather than the isolated Vesilute dipeptide, all research originates from Russian institutions, and no independent validation exists.

Researched for(5)

Rated by confidence in the evidence

  • Normalization of detrusor contractility and bladder smooth muscle function

    Speculative

    One 1993 animal study tested a related prostate extract, not this specific dipeptide; mechanism-based only.

    PMID 8330080 (Barabanova, Gorbachev, Parastaeva, Khavinson, Fiziol Zh Im I M Sechenova 1993;79(2):90-96)

  • Improvement of overactive bladder symptoms in women with detrusor overactivity

    Speculative

    No published clinical trials or registered studies support this specific claim.

    PubMed search returned no results (https://pubmed.ncbi.nlm.nih.gov/?term=%22detrusor+overactivity%22+peptide+bioregulator); no ClinicalTrials.gov entries for Vesilute

  • Tissue-specific gene expression regulation via epigenetic DNA interaction

    Low

    Multiple studies show short peptides of this class binding DNA and altering transcription in cells.

    PMID 34834147 (Peptide Regulation of Gene Expression: A Systematic Review, 2021); PMID 22708439 (Epigenetic aspects of peptide regulation of aging, 2012); PMID 31808038 (Peptide Regulation of Cell Differentiation, 2020)

  • Support for prostate health and reduction of lower urinary tract symptoms

    Speculative

    Prostate symptom data comes from a different, related prostate extract, not this specific dipeptide.

    PMID 8330080 (prostatilen extract, animal smooth-muscle work); no indexed clinical trials for the isolated dipeptide

  • Potential geroprotective effects via peptide bioregulation of aging tissues

    Speculative

    Rodent studies of related peptides show inconsistent results; none tested this specific dipeptide.

    PMID 11785104 (Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats, 2001); PMID 11586406 (Inhibitory effect of peptide vilon on induced rat urinary bladder tumors, 2001)

Benefits(5)

  • Normalization of detrusor contractility and bladder smooth muscle function

    Preclinical animal studies — Vezusten (bovine bladder polypeptide extract containing the Glu-Asp sequence) demonstrated normalization of detrusor contractility parameters in rat models with infravesical obstruction. The preparation showed a regulatory effect on the contractile activity of the muscles of the bladder wall and sphincter, relieving bladder hyperreflexivity. Barabanova et al. 1993 (Russian Journal of Physiology, 79(2):90-96) — prostatic peptides enhanced the functional activity of bladder smooth muscle cells in vitro, establishing early evidence for peptide-mediated regulation of bladder muscle contractility.

  • Improvement of overactive bladder symptoms in women with detrusor overactivity

    Kovalev et al. 2024 (Urology Herald / Vestnik Urologii) — A prospective cohort study of 20 women with overactive bladder syndrome confirmed by comprehensive urodynamic study. Each patient received ten intramuscular injections of the peptide regulator Vezusten (three visits per week). Results showed: daily urinations decreased from 14.0 to 11.0 (p < 0.001), episodes of urge incontinence improved significantly (p = 0.004), and maximum cystometric capacity increased from 267 to 320 ml. Authors concluded statistically significant improvement in subjective OAB symptoms but recommended further large placebo-controlled studies.

  • Tissue-specific gene expression regulation via epigenetic DNA interaction

    Khavinson & Popovich 2021 (Molecules, PMID 34834147) — Systematic review establishing that short peptides of 2-7 amino acid residues (including dipeptides like Vesilute) can penetrate cell nuclei, interact with nucleosomes, histone proteins, and single- and double-stranded DNA, and regulate DNA methylation status as an epigenetic mechanism for gene activation or repression. While not Vesilute-specific, this review provides the mechanistic framework for how the Glu-Asp dipeptide is proposed to exert tissue-specific bioregulatory effects in bladder cells.

  • Support for prostate health and reduction of lower urinary tract symptoms

    Kuzmenko et al. 2021 (Urologiia, PMID 34251104) — Study of 60 patients with benign prostatic hyperplasia (BPH) and chronic prostatitis. The main group received alpha-blocker plus fluoroquinolone therapy combined with bioregulatory peptides (Vitaprost), while the comparison group received standard therapy alone. The bioregulatory peptide group showed IPSS scores lower by 2.4 points, QOL scores lower by 1.2 points, NICH-CPSI scores lower by 2.5 points, white blood cell counts in prostate secretion 1.5x lower, and Qmax higher by 1.4 ml/sec after 2 weeks. While this study used Vitaprost (a prostate-derived peptide) rather than Vesilute directly, it demonstrates the efficacy of Khavinson-class bioregulatory peptides in the urogenital system.

  • Potential geroprotective effects via peptide bioregulation of aging tissues

    Anisimov & Khavinson 2010 (Biogerontology, PMID 19830585) — Review of long-term investigation into peptide bioregulators as geroprotectors. Treatment with peptide preparations increased mean lifespan by 20-40% and slowed age-related biomarker changes in rodents. While not Vesilute-specific, this review contextualizes the broader geroprotective rationale for tissue-specific Khavinson peptide bioregulators, including those targeting the aging urogenital system.

Key studies(5)

  1. The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation

    Prospective cohort study (human)20 women with OAB confirmed by urodynamic studyTen intramuscular injections (3 visits/week)

    Kovalev GV, Labetov IA, Shakirova RR, Shkarupa DD

    Urology Herald (Vestnik Urologii)

    2024

    Statistically significant improvement in subjective OAB symptoms in women with detrusor overactivity treated with the peptide regulator Vezusten (bovine bladder polypeptide extract). Daily urinations decreased from 14.0 to 11.0 (p < 0.001), urge incontinence episodes improved significantly (p = 0.004), and maximum cystometric capacity increased from 267 to 320 ml. Authors recommended further large placebo-controlled studies for confirmation.

  2. Russian urological research group

    Urologiia

    2024

    Comprehensive review devoted to the pathogenetic basis and clinical results of the drug Vesusten (polypeptides from animal bladder tissue) for the treatment of overactive bladder. Covers epidemiology, pathogenesis, current treatment methods, mechanisms of peptide regulation of physiological processes, and the results of preclinical and clinical studies of Vesusten. Preclinical studies confirmed absence of acute and chronic toxicity, carcinogenic, embryotoxic, mutagenic, immunotoxic, and teratogenic properties.

  3. Peptide Regulation of Gene Expression: A Systematic Review

    Systematic reviewN/A (systematic review of literature)

    Khavinson VKh, Popovich IG

    Molecules

    2021

    Established that short peptides consisting of 2-7 amino acid residues (including dipeptides like Vesilute's Glu-Asp) can penetrate cell nuclei and nucleoli, interact with nucleosomes, histone proteins, and DNA, and regulate DNA methylation as an epigenetic mechanism for gene activation or repression. Provides the mechanistic framework for all Khavinson bioregulatory dipeptides including Vesilute.

  4. The effect of prostatic peptides on the contractile activity of smooth-muscle cells from the bladder

    Experimental study (in vitro)Bladder smooth muscle cell culturesCell culture experiment

    Barabanova VV, Gorbachev AG, Parastaeva MM, Khavinson VKh

    Russian Journal of Physiology (Fiziologicheskii Zhurnal)

    1993

    Prostatilene (PST) peptides enhanced the functional activity of bladder smooth muscle cells. This early study established that organ-specific peptide bioregulators could modulate contractile activity of urogenital smooth muscle, providing foundational evidence for the subsequent development of bladder-targeted peptide bioregulators including Vesilute.

  5. Anisimov VN, Khavinson VKh

    Biogerontology

    2010

    Comprehensive review demonstrating that long-term treatment with peptide bioregulator preparations increased mean lifespan by 20-40%, slowed age-related biomarker changes, and suppressed spontaneous and induced tumorigenesis in rodents. Established the geroprotective rationale for tissue-specific short peptides including those targeting the urogenital system.

Regulation & availability

Why researchers look at it

Overactive bladder affects 30-40% of the elderly and current treatments carry anticholinergic side effects including cognitive impairment — a small study of 20 women with the related extract Vezusten showed significant improvements in urinary frequency and bladder capacity. Randomized trials exist for the Vezusten polypeptide extract, but their results cannot be assumed to apply to the pure Vesilute dipeptide. If independent trials confirmed efficacy, a simple two-amino-acid peptide improving age-related urinary function would be a novel approach to one of aging's most common quality-of-life problems.

Estimated cost
$30-80/mo oral capsules
FDA status
Not FDA-approved; no approved Vesilute product was identified, and it is not eligible for compounding in the US. Public records do not establish whether a confidential IND has been filed. In Russia, Vesilut is marketed as a dietary supplement, classified as a peptide food supplement (not a pharmaceutical) under the Cytogen product line from the St. Petersburg Institute of Bioregulation and Gerontology; FDA does not preapprove dietary supplements. While six Khavinson peptide bioregulators (Thymalin, Cortexin, Epithalamin, Samprost/Prostatilen, Retinalamin, and Thymogen) have been authorized by the Russian Ministry of Health as pharmaceuticals, Vesilute is not among them. Vezusten is a separate polypeptide preparation, and its research does not establish Vesilute approval.
WADA status
Not individually named on the 2026 List. S0 prohibits pharmacological substances not covered by later sections that lack current approval from any governmental health authority for human therapeutic use. A product-specific determination is needed; absence of FDA/EMA approval alone does not settle the worldwide criterion.
Prescribability
Vesilute is not an FDA-approved prescription medicine and is not eligible for compounding in the US. Public sources do not establish whether a confidential IND has been filed. In Russia and some CIS countries, Vesilut is marketed as an oral peptide bioregulator dietary supplement (classified as a 'Cytogen' peptide food supplement, not a pharmaceutical) produced under the Khavinson peptide bioregulator system. Some international longevity clinics and functional medicine practitioners may recommend Vesilute as part of bioregulator protocols for urogenital health, but this is outside conventional medical practice. Clinical studies of the separate Vezusten polypeptide medicine do not establish Vesilute's approval or efficacy.
Availability
Vesilute is available through several channels but is not part of mainstream Western medicine. In Russia it is sold as Vesilut capsules (Cytogen formulation), produced under the Khavinson peptide bioregulator system; the capsules contain the active synthesized dipeptide complex. It is classified there as a peptide food supplement, not a pharmaceutical, and no prescription is required in Russia. Some international longevity clinics, functional medicine and urological health practitioners incorporate Vesilute into bioregulator protocols for urogenital aging; no prescription is technically required for the supplement form in most jurisdictions. The related product Chitomur (A-12) is the natural bladder peptide complex (animal tissue extract) from which Vesilute's active sequence was identified; it is available as a capsule supplement, and manufacturers recommend taking it after completing a Vesilute course for sustained effects. Vesilute is not available through US or EU pharmacies, is not listed in any pharmacopeia outside Russia, and cannot be obtained through standard prescription channels.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(12)

  1. 1971
    Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
  2. 1992
    St. Petersburg Institute of Bioregulation and Gerontology is established as Khavinson's primary research center for peptide bioregulator development.
  3. 1993
    Barabanova et al. publish study demonstrating that prostatic peptides enhance contractile activity of bladder smooth muscle cells, providing foundational evidence for bladder-targeted peptide bioregulators (Russian Journal of Physiology, 79(2):90-96).
  4. 2000s (early)
    Vesilute (Glu-Asp dipeptide) is synthesized as a standalone bladder-targeted bioregulator at the St. Petersburg Institute, joining the Cytogen product line as the synthesized counterpart of Chitomur (A-12).
  5. 2010
    Anisimov & Khavinson publish comprehensive review of peptide bioregulation of aging, demonstrating 20-40% lifespan increase in rodents with peptide preparations (PMID 19830585, Biogerontology).
  6. 2010s
    Vesilut capsules become commercially available as a Cytogen dietary supplement in Russia.
  7. 2021
    Khavinson & Popovich publish systematic review on peptide regulation of gene expression, establishing the mechanistic framework for how dipeptides interact with DNA to regulate transcription (PMID 34834147, Molecules).
  8. 2021
    Kuzmenko et al. publish study of bioregulatory peptides in BPH and chronic prostatitis (n=60), demonstrating enhanced therapeutic benefit when combined with standard therapy (PMID 34251104, Urologiia).
  9. 2024
    Kovalev et al. publish prospective cohort study of Vezusten (bladder polypeptide extract) in 20 women with overactive bladder, demonstrating statistically significant improvements in urinary frequency and bladder capacity (Urology Herald).
  10. 2024
    Review of bioregulatory therapy for overactive bladder published in Urologiia, consolidating preclinical and clinical evidence for Vesusten (PMID 39563546).
  11. 2025
    ICS-EUS 2025 Abstract #99 reports before-and-after observations in 48 patients receiving Vezusten; it does not describe randomization or a beta-3 agonist comparator.
  12. 2026-03
    No FDA-approved Vesilute product identified. Public sources do not establish whether a confidential IND has been filed. Russian Vesilut is marketed as an oral dietary supplement.

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is Vesilute and what is it made of?

Vesilute is a synthetic dipeptide (two amino acids) consisting of glutamic acid and aspartic acid (Glu-Asp, or ED in single-letter code). It has the molecular formula C9H14N2O7 and a molecular weight of 262.20 g/mol. It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthesized peptide bioregulator targeted to bladder and urogenital tract tissues. It is the synthetic counterpart of Chitomur (A-12), a natural peptide complex extracted from animal bladder tissue.

What is the difference between Vesilute, Chitomur, and Vezusten?

Vesilute (Vesilut) is the synthesized Glu-Asp dipeptide (Cytogen class), representing the minimal active peptide sequence targeting bladder tissue. Chitomur (A-12) is the natural peptide complex (Cytomax class) extracted from animal bladder wall tissue, containing a mixture of short peptides including the Glu-Asp sequence. Vezusten (Vesusten) is a pharmaceutical-grade preparation of polypeptides isolated from bovine bladder tissue, used in clinical studies for overactive bladder treatment (administered via intramuscular injection). Vesilute has faster onset but shorter duration of effect, while Chitomur's effects are reported to persist for 6-12 months. Manufacturers recommend using Chitomur after completing a Vesilute course for sustained benefit.

Is Vesilute safe? Are there side effects?

Published preclinical studies of the related preparation Vezusten indicate the absence of acute and chronic toxicity, and no carcinogenic, embryotoxic, mutagenic, immunotoxic, teratogenic, local irritant, or allergenic effects were observed. Khavinson peptide bioregulators as a class are reported to have no significant adverse events across their entire history of clinical use, with the only noted contraindication being individual intolerance to capsule components (gelatin shell or excipients). However, all safety data originates from Khavinson-affiliated research groups, no independent safety monitoring has been conducted, and sample sizes are very small. Contraindications listed by manufacturers include pregnancy, breastfeeding, and individual component intolerance.

Can Vesilute help with overactive bladder or urinary incontinence?

A 2024 prospective cohort study of 20 women with overactive bladder treated with Vezusten (the related polypeptide extract) showed statistically significant improvements in daily urination frequency (14 to 11, p<0.001), urge incontinence (p=0.004), and maximum cystometric capacity. That study was small, non-randomized and had no placebo control; its authors recommended large placebo-controlled studies for confirmation. Vezusten also has an earlier randomized placebo-controlled trial, but these studies used the polypeptide extract rather than the isolated Vesilute dipeptide. Vesilute should not be considered a proven treatment for OAB or incontinence.

How does Vesilute work at the molecular level?

Vesilute is proposed to work through the Khavinson peptide bioregulation mechanism: ultrashort peptides of 2-7 amino acids cross cell membranes and enter the nucleus, where they interact with DNA to regulate gene expression through epigenetic mechanisms. Specifically, short peptides have been shown to penetrate the major groove of DNA, interact with nucleosomes and histone proteins, and regulate DNA methylation status. For bladder tissue, this is proposed to normalize protein synthesis in urothelial and smooth muscle cells, regulate detrusor contractility, and modulate inflammatory and regenerative pathways. The exact DNA binding sites and gene targets specific to the Glu-Asp dipeptide in bladder tissue have not been published.

Is the research on Vesilute credible?

The research is at an early stage and has significant limitations. The synthesized Vesilute dipeptide itself has very few dedicated studies. Most clinical evidence comes from Vezusten (polypeptide extract), not the isolated dipeptide. Kovalev et al. 2024 was a small uncontrolled cohort, but Vezusten also has an earlier randomized placebo-controlled trial. Neither establishes the efficacy of isolated Vesilute. All studies originate from Russian institutions affiliated with Khavinson's research program. No independent replication by Western or international research groups has been published. The mechanistic framework (short peptide-DNA interaction) is supported by the broader Khavinson literature published in PubMed-indexed journals (Molecules, Biogerontology, Advances in Gerontology), but independent validation of this mechanism by other research groups remains limited.